Introduction
Radiotherapy is a major cancer therapy along with chemotherapy and surgery. Radiotherapy utilizes ionizing radiation such as X-ray, gamma-ray and electron beams to treat cancers. Radiotherapy is provided to cancer patients alone or in combination with surgery or chemotherapy as a curative therapy, adjuvant therapy, and palliative care. The role of radiotherapy is readily demonstrated by the fact that, while the use of radiotherapy dose vary depending on the types of cancer being treated, overall, more than 50% of all the cancer patients require radiotherapy sometime during the course of the treatment of their illnesses.
There are three main ways of delivering radiotherapy: 1) External radiotherapy or teletherapy is the delivery of beams produced by a source outside of the body.
2) Internal radiotherapy or brachytherapy is the delivery of the radioactive source via an implanted unit.
3) Unsealed source is the process of attaching a radioactive isotope to a chemical/metabolite and injecting into the body. This has been used in neuroblastoma patients.
Radiotherapy, the treatment of cancer by radiation, can, in many cases, save lives. Even in cases where the disease is too advanced to be cured, radiotherapy can provide palliation that allows patients to live out their lives as comfortable as possible. Radiotherapy remains an unattainable treatment option, with only 25% of patients having access to the radiotherapy treatment in low and middle income countries compared to 50% -60% in high income countries. The International Atomic Energy Agency (IAEA) established the Advisory Group on increasing access to Radiotherapy Technology in low and middle income countries (AGaRT) in 2009 under the Programme of Action for Cancer Therapy (PACT). AGaRT acts as a neutral facilitator to bring together radiotherapy users and major radiotherapy equipment suppliers, to encourage dialogue that will ensure that the unique radiotherapy service requirements of developing countries are met by the technology available [1] . According to data from IAEA-DIRAC database, 10/2010, 1 -2 million people are served by one radiotherapy unit in Pakistan and India. By 2020, annual cancer cases in LMICs are expected to rise by 30%, to 10.3 million.
Teletherapy by accelerator is clinically administered by the application of electro-magnetic radiation or electrons. Electromagnetic radiation may be X-rays; radiation produced, when an accelerated electron hits a target.
• Contact therapy < 100 kV.
• Superficial voltage ~100 kV.
• Orthovoltage ~150 -300 kV.
• Megavoltage ~4 MeV -25 MeV.
The γ rays are emitted from radioactive elements or isotopes. While
226
Ra and
137
Cs have been used as gamma emitters, the modern radiotherapy department frequently relies on 60 Co teletherapy machines which operate as megavoltage equipment.
Brachytherapy is the administration of radiation therapy by placing radioactive sealed source adjacent to or into tumours or body cavities. With this mode of therapy, a high radiation dose can be delivered locally to the tumour with rapid dose fall-off in the surrounding normal tissues. In the past, brachytherapy was carried out mostly with Radium or Radon sources in the world. Currently, use of artificially produced radionuclides such as 137 Cs, 192 Ir, and 125 I, is rapidly increasing. 192 Ir sealed radioactive sources are generally employed for brachytherapy applications in Pakistan.
According to the removal of the radioactive sources, brachytherapy implants can be Temporary (sources are inserted and later removed) or Permanent (sources are inserted and left in place for the remainder of their active life).
According to the dose rate of the sources used, brachytherapy can be: • Low Dose-Rate (LDR): 0.4 to 2.0 Gy per hour.
• Medium Dose-Rate (MDR): 2.0 to 12.0 Gy per hour.
• High Dose-Rate (HDR): >12.0 Gy per hour.
By International Commission on Radiation Units and Measurements (ICRU) definition, HDR is >12.0 Gy/h, although the usual dose rate employed in current HDR brachytherapy units is about 100 -300 Gy per hour.
There are alternative methods of irradiating tumours, some virtually abandoned e.g. fast neutrons, and some under investigation e.g. protons, heavier ions, and boron neutron capture therapy. In boron neutron capture, tumours containing boron are irradiated with low energy (epithermal) neutrons to produce short-range alpha particles which are very efficient in killing cells. All these techniques are under development. In Pakistan teletherapy and brachytherapy is practiced. Unsealed sources of Iodine-131 and Phosphorus-32 have been routinely employed for the treatment of thyroid and blood disorders in Pakistan. Few radiolabeled compounds ( Lu-EDTMP) have also been used for bone pain palliation.
Cancer Statistics
In Pakistan we do not have a National Cancer Registry. Some institutions are now starting to develop their own Cancer Registry. According to the World Health Organisation annually 120,000 people in Pakistan are diagnosed with cancer. There were more than 1.4 million cancer patients in Pakistan. More than 80,000 people died each year due to this disease, including 40,000 from breast cancer. [3] . A total of 16,351 cancer patients were registered at KIRAN during the nine-year period. Male cancers accounted for 48.1% and female cancers 51.8%. Some 558 (3.4%) were in children (0 -15 years). The mean ages at presentation for males and females were 50 ± 9.6 and 47 ± 7.4 years respectively. In males the five most frequent malignancies were head and neck (32.6%), lung (15%), gastrointestinal tract (GIT) (6.9%), lymphoma (6.1%), and bone and soft tissue (4.9%). In females breast cancer was the most common cancer accounting for 38.2% followed by head & neck (15.1%), cervical (5.5%), ovarian (4.9%) and GIT cancer (4.9%) respectively. Overall cancer incidence in nine years in the KIRAN tertiary care cancer institution showed that head and neck cancers in males and breast cancers in females are most common, at rates almost highest in Asia. Mean age and male to female ratio in all other cancers are essentially comparable to other developing countries.
Pakistan Atomic Energy Commission (PAEC) was operating 14 Nuclear Medical Centers in 2011. The total patient turnover from 2005-2011 is given in Table 1 [4] .
Radiation Oncology Infrastructure
Estimates of radiation oncology infrastructure in Pakistan for the years 2004 and 2009 in order to quantify trends in radiotherapy facilities, patient load and to identify the future needs were performed by N. Begum et al. [5] . In another survey in 2009 showed that each radiotherapy centre covered a mean population of 1.96 million (range 3.54 -19.63), with more access of cancer patients to the public sector due to low costs of radiotherapy treatment. There were only 56 radiation oncologists, 55 medical physicists, and 145 radiotherapy technologists. Further, only 20 Cobalt-60, 17 linear accelerators, 12 fluoroscopic simulators, and 4 CT simulators were available [6] . The majority of modern equipment and treatment delivery was available in the private sector. An estimated 55% -60% of all new cases of cancer were currently being referred for radiotherapy each year, and the existing services were inadequate.
In external beam radiation therapy (EBRT), the quality assurance (QA) of the radiation beam is crucial to the accurate delivery of the prescribed dose to the patient. One of the dosimetric parameters that require monitoring is the beam output, specified as the dose rate on the central axis under reference conditions. The International Atomic Energy Agency (IAEA)/World Health Organisation (WHO) postal audit dosimetry service provides an independent verification of dose rate calibration protocol by an international facility. Three photon beams were audited: a 6 MV beam from the low-energy linac and 6 and 18 MV beams from a dual high-energy linac. The agreement between Department of Radiation Oncology, Aga Khan University Karachi stated doses and the IAEA results was within 1% for the two 6 MV beams and within 2% for the 18 MV beam [7] . Under the Regional Cooperative Agreement for Research, Development and Training related to Nuclear Science and Technology (RCA), 15 Member States of the International Atomic Energy Agency (IAEA) in the Asia and the Pacific region (Bangladesh, China, India, Indonesia, Japan, Republic of Korea, Malaysia, Mangolia, Mynmar, Pakistan, Philippines, Singapore, Sri Lanka, Thailand, Vietnam) have joined together to focus efforts on the issue of improving cancer treatment. The RCA project on "Improvement in Quality of Radiotherapy for Frequent Cancers in the Regions" (RAS/6/040) was successfully implemented between 2005 and 2008. The RCA Member States recognized the importance of the role and the contribution of radiotherapy to cancer treatment and care, and decided to produce a success story as a means to better inform for the wider public in the region. The overall objective was to improve the quality of the radiotherapy in recipient RCA Member States through enhancing national capacities in brachytherapy, improving the quality assurance in radiotherapy through the use of mission by the Quality Assurance Team on Radiation Oncology (QUATRO missions) and the adoption of QUATRO audit methodology [8] .
Pakistan Nuclear Regulatory Authority (PNRA) in regulatory guide has described regulatory requirements for medical teletherapy facilities. It includes requirements for medical exposure, particularly general and design requirements for superficial, deep X-ray therapy, megavolt and electron beam therapy and sealed sources therapy facilities. The guide may be of interest for those who are concerned with the installations and design of new radiation facilities. Computation of protective barriers for shielding design of teletherapy facilities is also mentioned. This guide is intended mainly for use by medical physicists, radiotherapists and operators of teletherapy facilities who are directly responsible with radiation protection requirements [9] . 
Role of IAEA
Research activities supported by the International Atomic Energy Agency (IAEA), through Coordinated Research Program CRPs, are designed to encourage the acquisition and dissemination of new knowledge from the use of nuclear technologies and isotopic techniques. The CRPs bring together developing and developed countries to concentrate on the same research topic at the same time, and help the countries in sharing and using the knowledge and experience gained. A large number of CRPs were conducted by the IAEA and Regional Cooperation Agreement (RCA) to promote the radiotherapy activities for management of cancer in different parts of the world. Pakistan participation in CRPs on radiotherapy related topics are given in Table 2 [11].
Radiotherapeutics Production
At present almost 40 nuclear medical centers are functioning where more than one million patients are treated yearly. Radiopharmaceuticals are extensively used for therapeutic and diagnostic purposes in the nuclear medical centers. Isotope Production Division, PINSTECH, Islamabad is supplier of radiopharmaceutical to these centers. Nearly all nuclear medical centers perform diagnostic imaging, but ~25 centers perform radiotherapy. Charged particle accelerators and nuclear reactors are employed for production of radioisotopes, however in bulk amounts these are produced in nuclear reactors [12] [13] . Production of radioisotopes started since Pakistan Research Reactor-1 (PARR-I) went critical in December 1965. The PARR-1 is a swimming pool type research reactor originally designed for a thermal power of 5 MW. Its core has been redesigned to operate with LEU fuel at a power level of 9 MW in 1992 and 10 MW in 1998.
Flux traps have been provided for incore irradiation of samples. In the first high power core the unperturbed neutron flux in the flux traps varies from 3.5 × 10 13 to about 2 × 10 14 with an average of about 1.3 × 10
14
. In the equilibrium core, average thermal neutron flux of the order of 6 × 10 13 and 1.6 × 10 14 n/cm·s is expected at locations F-4 and C-7, respectively. In addition, the area outside the graphite reflector can be utilized for core side irradiation.
During irradiation of target a number of radionuclides of different half-lives and energies can be produced along with the radioisotope of interest. The irradiated target will often require chemical processing to separate the radioisotope of interest. Various facilities available for radioisotope processing are as follows:
1) Iodine-131 production cell (wet distillation technique). Maximum capacity per batch 10 Ci/370 GBq; 2) Iodine-131 production cell (dry distillation technique). Maximum capacity per batch 10 Ci/370 GBq; 3) Phosphorus-32 production cell (dry distillation technique). Maximum capacity per batch 10 Ci/370 GBq; 4) Sulpher-35 production glove box; 5) Molybdenum-99 loading facility for preparation of 99m Tc generators; 6) Mo-99 (fission) production facility; 7) Hot cell with master slave manipulators; 8) Fume hoods and glove boxes (for small scale production of different radionuclides and R&D work); 9) Workshop for target preparation and sealed source fabrication; 10) Laboratories for determination of radionuclidic, radiochemical and biological purity. 
Production of Iodine-131

Wet Distillation Technique
The neutron irradiated tellurium is dissolved in an oxidizing medium (chromic and sulphuric acid) converting tellurium to telluric acid wherein the elemental iodine is released and converted to iodic acid (HIO 3 ). This is reduced with oxalic acid releasing elemental iodine vapor, (distilled at 140˚C) which is collected in alkaline scrubbers as sodium iodide in sodium sulphate/sodium bisulphate/NaOH solution.
Dry Distillation Technique
The irradiated tellurium dioxide is heated at a temperature ~700˚C under vacuum. The 131 I released from the matrix of the target as vapor is then trapped in carbonate/bicarbonate buffer.
Thyroid disorders are treated by 131 I [14] . Weekly demand of Iodine-131 in Pakistan is 4 -5 Ci. Iodine-131 labeled MIBG (20 -30 mCi) by isotope exchange method is also prepared for diagnostic applications. To minimize the radiation exposure of paramedical staff facility for preparation of Iodine-131 capsules for diagnosis and therapy are underway. Sixteen nuclear medical centers are using NaI ( 131 I) for the treatment of hyperthyroidism and well-differentiated thyroid cancer.
Production of Phosphorus-32
Neutron irradiated Sulfur is distilled at 450˚C in a quartz furnace. Residual 32 P is dissolved in dilute HCl and H 2 O 2 and finally purified by passing through cation exchange column. The product obtained is H 3 PO 4 . Yearly demand of 32 P is <0.5 Ci. Small-scale production of 32 P is obtained by extraction in boiling water from neutron irradiated sulfur and purified by passing through cation exchange column. Sodium orthophosphate ( 32 P) is used by 10 medical centers for the treatment of blood disorders. 
Other Beta Emitting Radionuclides Production
Radionuclides that decay by β − particle emission are used most extensively for radiotherapeutic applications in current clinical practices [15] . Utilization of β − particle emitters provides a mechanism to produce a highly homogenous radiation dose even though their deposition is heterogeneously distributed in tumors. Radiochemical separation methods have been developed for obtaining no-carrier-added isotopes from neutron irradiated target matrix activity. Table 3 gives the details of target material, technique and the radionuclide produced in no-carrier-added or carrier added form [16] - [25] .
Most work with Re-DEDC and HDD radiopharmaceuticals that are used for liver cancer therapy. Different concentration techniques using ion exchange and solvent extraction techniques have been developed at our institute [26] - [29] .
Various radiolabeled compounds (peptides, colloid and bone seeking agent etc.) for radiotherapy have been synthesized and clinically evaluated. The radionuclide used during these studies includes 90 [38] . Various IAEA CRPs on radiotherapeutic applications of labeled compounds have been carried out at different nuclear medical centers in Pakistan [11] , however the radionuclides were produced at Pakistan Institute of Nuclear Science and Technology (PINSTECH) Islamabad (Table 3 ).
Conclusion
The facilities of diagnostic procedures are well established in Pakistan; however, radiotherapy units and use of radiotherapeutics are not up to mark. New facilities for radiotherapy are needed to fight increasing cases of cancer in the country. Use of radiotherapeutics, which can be produced locally, shall be enhanced for patient management.
